India Biotech Startup Gets $4.2M for Shelf-Ready Cancer Care

Cancer cell therapy has transformed survival rates for some patients, but most people can't access it because each treatment must be custom-made from their own cells at enormous cost and delay.

East Ocyon Bio is working on a different model. The company is developing cancer treatments made from healthy donor cells that can sit on a shelf until needed, ready to use when a patient walks in the door.

Founded in 2022 in Gurugram, the biotech startup recently closed a $4.2 million seed round led by Aeravti Ventures and pharmaceutical company Micro Labs. The funding will support pre-clinical testing and build a manufacturing facility that meets global quality standards.

The company uses natural killer cells, part of the immune system's defense team, engineered with a targeting mechanism that directs them at cancer cells. These CAR-NK therapies don't require a match to the patient, which is why they can be made ahead of time.

Co-founder and CEO Dinesh Kundu wants to bring advanced treatments to Indian patients at the same time they launch globally, not years later. The team is also working on treatments for autoimmune disorders and rare diseases.

In February, India's Technology Development Board awarded the company a grant to develop CAR-NK therapy for hard-to-treat tumors and leishmaniasis, a parasitic disease affecting vulnerable populations. The government backing signals confidence in building this capability domestically.

The science is still early. None of East Ocyon Bio's therapies have been tested in people yet, and the company hasn't announced when human trials will begin. With 14 employees and minimal revenue so far, it's a startup in the truest sense.

But the potential matters. Current CAR-T therapy can trigger severe immune reactions and costs hundreds of thousands of dollars per patient. CAR-NK is considered safer and more scalable, though it's still being proven worldwide.

The Ripple Effect

If East Ocyon Bio succeeds, the impact extends beyond individual patients. India carries a massive burden of unmet medical need, and advanced cancer treatments remain out of reach for most of the population due to cost and availability.

A domestic platform for off-the-shelf cell therapy could reduce India's dependence on imported treatments and create a model for other developing nations facing similar gaps. The company is building infrastructure that could eventually produce multiple types of therapies from the same facility.

The work also positions India as a contributor to global biotech innovation rather than just a recipient, potentially attracting more investment and talent to the country's life sciences sector.

Right now, East Ocyon Bio is in the long, unglamorous phase of lab work and facility building that comes before any dramatic breakthroughs. But the foundation they're laying could change what's possible for cancer patients across India and beyond.